Business Context and Reporting Period
This Form 6-K filing by GSK plc (the "Company") reports a transaction in its own shares for the month of October 2025. The filing details a share repurchase executed on October 21, 2025, acting through BNP Paribas SA as the broker. The transaction is part of an existing buyback programme established under a non-discretionary agreement announced on September 30, 2025.
Key Financial Metrics
The filing focuses exclusively on capital structure and share repurchase activity. It does not contain revenue, profit, cash flow, margin, debt, or liquidity data.
- Shares Purchased (Oct 21, 2025): 250,000 ordinary shares.
- Price Range: Lowest 1,635.00p; Highest 1,650.00p.
- Volume-Weighted Average Price (VWAP): 1,642.48p.
- Total Buyback Since Sept 30, 2025: 5,113,500 ordinary shares.
- Treasury Shares Held: 252,578,344 ordinary shares.
- Shares in Issue (excluding Treasury): 4,062,838,575 ordinary shares.
- Total Voting Rights: 4,062,838,575.
- Treasury Voting Rights Percentage: 6.22%.
Material Changes
Following the purchase on October 21, 2025, the Company's treasury shareholding increased to 252,578,344 shares. Consequently, the percentage of voting rights attributable to treasury shares stands at 6.22%. The number of ordinary shares in issue remains 4,062,838,575. The filing does not provide comparative financial data for prior periods to assess material changes in operating performance.
Guidance, Outlook, and Risks
The filing contains no specific financial guidance, outlook, or management commentary regarding future earnings or operational strategy. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks and uncertainties. These risks are referenced as being described in the "Risk Factors" section of GSK's Annual Report on Form 20-F for 2024 and its Q2 Results for 2025. No unusual items or contingencies are disclosed in this specific report.
Investor Verification Checklist
- Verify the total remaining authorization under the buyback programme announced on September 30, 2025.
- Confirm the impact of the 6.22% treasury shareholding on earnings per share (EPS) calculations.
- Review the referenced 2024 Form 20-F and 2025 Q2 Results for detailed risk factors and financial performance context.
- Monitor future 6-K filings for updates on the buyback programme's progress and completion status.